Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates (BLEST)

Sun Yat-sen University

Status and phase: Completed; Phase 4

Conditions: Non-small Cell Lung Cancer; Bone Metastases

Treatments: Drug: bisphosphates

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00765687

CZOL446ECN07

Details and patient eligibility

About

A multicenter Prospective Study to assess the screening methods, parameter of NTX and the efficacy and safety of zoledronic acid treatment in addition to anti-tumor therapy in patients of non-small cell cancer with bone metastasis in china.

Enrollment: 432 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Age >18, either sex
2. Histologically confirmed non-small cell cancer
3. One bone metastasis at least confirmed by image(X ray,CT or others)
4. Without receiving zoledronic acid
5. Life expectancy > 6 M
6. ECOG <= 2
7. Signed ICF

Exclusion criteria

1. Women who are pregnant or in lactation
2. Patients with hyperostosis
3. with brain metastasis(exception of those without symptom or with Metastasis Lesions under controlled
4. Previous or current treatment with any other bisphosphonates, bone- protecting, cytotoxic or targeted therapy
5. Severe co-morbidity of any type that may interfere with assessment of the patient for the study -

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

432 participants in 1 patient group

Observation

No Intervention group

Treatment:

Drug: bisphosphates